title: Early experience with stenting for iliac occlusive disease.
abstract: OBJECTIVE
  To review our experience of iliac artery stenting for occlusive disease.
  
  
  METHODS
  Prospective study of 50 consecutive patients with iliac occlusive disease, November 1993-November 1996. The indications for stenting were complete iliac occlusion (37) restenosis (four), donor site inflow for bypass grafting (four) and difficult stenoses (> 90% and/or > 5 cm) (five). The majority of patients (41) presented with intermittent claudication.
  
  
  RESULTS
  All 13 stenoses were successfully stented. One occluded but the rest remain patent. There were no other complications. By contrast, it was not possible to place a stent across 10 of the 37 complete iliac occlusions. In this group there were nine major complications, including five patients who required early embolectomy (four femoral, one brachial) and one patient who developed a false aneurysm at the site of the stent. The "intention to treat" primary cumulative patency for iliac occlusions was 65% at 2 years but after excluding technical failures was 88%.
  
  
  CONCLUSIONS
  There is a sharp learning curve and significant complication rate associated with stenting complete occlusions. However, following successful stenting patency rates are around 90% for both iliac stenoses and occlusions.
authors.affiliation: Department of Surgery, Royal Berkshire Hospital, Reading, U.K.
authors.forename: G J
authors.initials: GJ
authors.lastname: Toogood
authors.forename: E P
authors.initials: EP
authors.lastname: Torrie
authors.forename: T R
authors.initials: TR
authors.lastname: Magee
authors.forename: R B
authors.initials: RB
authors.lastname: Galland
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001157:Arterial Occlusive Diseases / Q000601:surgery*; D005260:Female; D006801:Humans; D007083:Iliac Artery / Q000601:surgery*; D007858:Learning; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015607:Stents / Q000009:adverse effects; D014656:Vascular Surgical Procedures / Q000009:adverse effects*